← Oncology Approval Tracker

FDA DECISION ·

Keytruda / Keytruda Qlex + paclitaxel

pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph with paclitaxel, with or without bevacizumab · Merck

FDA approvalNew or expanded indicationOvarian and related cancers
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma, a PD-L1 CPS of at least 1 on an FDA-authorized test, and one or two prior systemic regimens.

LAMPGEN ANALYSIS

Why it matters

PD-L1 status now identifies a treatment option in a defined platinum-resistant population. The option to include bevacizumab matters when describing the regimen and comparator.

What research teams should watch

Verify the PD-L1 result, prior lines and platinum resistance criteria. Maintain clear attribution when patients receive several agents with overlapping safety responsibilities.

PRIMARY RECORDS

Sources